Finally, the long-term, whole-body effects of administering a peptide that is normally restricted to the stomach remain completely unknown
It is especially beneficial for people with diagnosed B12 deficiency, which can cause fatigue, weakness, and difficulty losing weight
Plasma MOTS-c itself is not yet widely available as a clinical laboratory test, though research assays exist
BPC-157 has no approved therapeutic indication in humans and is not recognized as a medicine, supplement, or drug by Health Canada
In rare cases, B12 deficiency can be caused by pernicious anemia
the STEP-1 trial reported approximately 14.9 percent on semaglutide over 68 weeks